Back to Search
Start Over
[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
- Source :
-
Deutsche medizinische Wochenschrift (1946) [Dtsch Med Wochenschr] 2011 Nov; Vol. 136 (44), pp. 2267-70. Date of Electronic Publication: 2011 Oct 25. - Publication Year :
- 2011
-
Abstract
- Roflumilast is a new drug with innovative pharmacodynamic properties for use in patients with chronic obstructive pulmonary disease (COPD). By selective inhibition of phosphodiesterase-4 roflumilast targets inflammatory processes in COPD, with beneficial effects on smoking-induced bronchial inflammation, fibrotic remodeling, mucociliary malfunction and oxidative stress.<br /> (© Georg Thieme Verlag KG Stuttgart · New York.)
- Subjects :
- Aminopyridines adverse effects
Aminopyridines pharmacokinetics
Benzamides adverse effects
Benzamides pharmacokinetics
Bronchodilator Agents adverse effects
Bronchodilator Agents pharmacokinetics
Bronchodilator Agents therapeutic use
Contraindications
Cyclopropanes adverse effects
Cyclopropanes pharmacokinetics
Cyclopropanes therapeutic use
Double-Blind Method
Drug Interactions
Drug Therapy, Combination
Forced Expiratory Volume drug effects
Humans
Mucociliary Clearance drug effects
Oxidative Stress drug effects
Phosphodiesterase 4 Inhibitors adverse effects
Phosphodiesterase 4 Inhibitors pharmacokinetics
Randomized Controlled Trials as Topic
Smoking adverse effects
Aminopyridines therapeutic use
Benzamides therapeutic use
Phosphodiesterase 4 Inhibitors therapeutic use
Pulmonary Disease, Chronic Obstructive drug therapy
Subjects
Details
- Language :
- German
- ISSN :
- 1439-4413
- Volume :
- 136
- Issue :
- 44
- Database :
- MEDLINE
- Journal :
- Deutsche medizinische Wochenschrift (1946)
- Publication Type :
- Academic Journal
- Accession number :
- 22028292
- Full Text :
- https://doi.org/10.1055/s-0031-1292040